| Date | Form | Description | Docs | XBRL | Pages |
| 03/24/21 | 8-K | Current report filing |
|
25 | |
| 03/24/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/23/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 | |
| 03/22/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/11/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
30 |
| 02/05/21 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
3 | |
| 02/05/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 02/01/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/28/21 | 8-K | Current report filing |
|
2 |
Latest News & Events
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium
Read More...Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Read More...Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
Read More...